Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

China Pharma Holdings (CPHI) EBIT (2016 - 2025)

China Pharma Holdings (CPHI) has disclosed EBIT for 16 consecutive years, with -$628145.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, EBIT rose 42.12% year-over-year to -$628145.0, compared with a TTM value of -$3.2 million through Sep 2025, down 24.65%, and an annual FY2024 reading of -$4.6 million, down 496.19% over the prior year.
  • EBIT was -$628145.0 for Q3 2025 at China Pharma Holdings, up from -$652120.0 in the prior quarter.
  • Across five years, EBIT topped out at $1.4 million in Q4 2022 and bottomed at -$1.4 million in Q2 2024.
  • Average EBIT over 5 years is -$485317.8, with a median of -$713542.0 recorded in 2023.
  • Peak annual rise in EBIT hit 223.64% in 2021, while the deepest fall reached 1104.13% in 2021.
  • Year by year, EBIT stood at $1.4 million in 2021, then increased by 3.25% to $1.4 million in 2022, then crashed by 43.28% to $797625.0 in 2023, then plummeted by 249.95% to -$1.2 million in 2024, then skyrocketed by 47.48% to -$628145.0 in 2025.
  • Business Quant data shows EBIT for CPHI at -$628145.0 in Q3 2025, -$652120.0 in Q2 2025, and -$758618.0 in Q1 2025.